RxDoctor Payments DataLook up a doctor →

Lacey Vasilakis

Nurse Practitioner · Lake Charles, LANPI 1083056915

Payments from drug & device makers

$16,895in general payments, 2019–2025

Across 620 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$4K
  • Novartis$2K
  • AstraZeneca$933
  • Merck$804
  • Daiichi Sankyo Inc.$629
  • Takeda Pharmaceuticals U.S.A., Inc.$599
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$3,75022%
  • Food & beverage$11,69969%
  • Education$7815%
  • Other$6654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC26$3,720
Novartis68$1,735
AstraZeneca47$933
Merck37$804
Daiichi Sankyo Inc.26$629
Takeda Pharmaceuticals U.S.A., Inc.24$599
Bristol Myers Squibb35$594
Astellas Pharma US Inc19$535
Amgen26$514
Eli Lilly1$500
Pfizer24$468
Johnson & Johnson(2 entities)21$412
Eisai Inc.19$333
Sanofi16$326
E.r. Squibb & Sons, L.L.C.15$274
Genmab U.S., Inc.13$273
Bayer12$270
Beigene USA, Inc.10$220
Incyte Corporation12$215
Sobi, Inc7$206
Genentech USA, Inc.10$197
Sanofi-aventis U.S. LLC2$193
Seagen Inc.6$180
Taiho Oncology, Inc.9$177
Boehringer Ingelheim8$166
Puma Biotechnology, Inc.9$161
AbbVie7$151
Regeneron Healthcare Solutions, Inc.7$148
Stemline Therapeutics Inc.8$139
Adaptive Biotechnologies Corporation5$134
Mirati Therapeutics, Inc.8$127
Jazz Pharmaceuticals Inc.5$120
Exelixis Inc.7$118
EMD Serono, Inc.6$113
Ipsen Biopharmaceuticals, Inc6$111
Servier Pharmaceuticals LLC5$108
AVEO Pharmaceuticals, Inc.3$87
Blueprint Medicines Corporation5$84
GSK3$68
Pharmacosmos Therapeutics Inc.5$63
Array Biopharma Inc4$62
Gilead3$52
Progenics Pharmaceuticals, Inc.2$48
Tempus AI, Inc2$44
Geron Corporation2$41
Beone Medicines USA, Inc.2$41
Global Blood Therapeutics, Inc.2$38
Springworks Therapeutics, Inc.2$37
Tersera Therapeutics LLC1$32
Karyopharm Therapeutics Inc.2$31
Catalyst Pharmaceuticals, Inc.1$24
Legend Biotech USA Inc.1$24
Syndax Pharmaceuticals, Inc.1$23
Acrotech Biopharma Inc.1$22
Acceleron Pharma, Inc.1$20
Recordati_rare_diseases_inc.1$20
Dova Pharmaceuticals1$20
Rigel Pharmaceuticals, Inc.1$16
Agios Pharmaceuticals, Inc.1$16
Chiesi USA, Inc.1$15

How this compares

$16,895 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,790
Medicare patients
107
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib41$670,011
ImbruvicaIbrutinib30$543,023
PomalystPomalidomide18$410,935
RevlimidLenalidomide18$363,391
Lenalidomide21$329,127
XtandiEnzalutamide13$184,315
VerzenioAbemaciclib11$182,836
Sunitinib Malate12$155,131
SancusoGranisetron15$9,401
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen184$5,581
Morphine Sulfate31$2,015
Oxycodone Hcl48$1,837
Anastrozole106$1,681
Exemestane14$1,419
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$468$670,01141 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$274$410,93518 claims
Bristol Myers SquibbRevlimid$594$363,39118 claims
Astellas Pharma US IncXtandi$535$184,31513 claims
Lilly USA, LLCVerzenio$3,720$182,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →